Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells

BACKGROUND: The Gab2 docking protein acts as an important signal amplifier downstream of various growth factor receptors and Bcr-Abl, the driver of chronic myeloid leukaemia (CML). Despite the success of Bcr-Abl tyrosine kinase inhibitors (TKI) in the therapy of CML, TKI-resistance remains an unsolv...

Descripción completa

Detalles Bibliográficos
Autores principales: Halbach, Sebastian, Rigbolt, Kristoffer TG, Wöhrle, Franziska U, Diedrich, Britta, Gretzmeier, Christine, Brummer, Tilman, Dengjel, Jörn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640961/
https://www.ncbi.nlm.nih.gov/pubmed/23607741
http://dx.doi.org/10.1186/1478-811X-11-30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640961/
https://www.ncbi.nlm.nih.gov/pubmed/23607741
http://dx.doi.org/10.1186/1478-811X-11-30

Ejemplares similares